Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma
Open accessThe DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.
Abstract
Glaucoma is a group of optic neuropathies associated with aging and sensitivity to intraocular pressure (IOP). Early progression involves retinal ganglion cell (RGC) axon dysfunction that precedes frank degeneration. Previously we demonstrated that p38 MAPK inhibition abates axonal dysfunction and slows degeneration in the inducible microbead occlusion model of glaucoma in rat. Here, we assessed the neuroprotective effect of topical eye delivery of the p38 MAPK inhibitor BIRB 796 in three models of glaucoma (microbead occlusion in rat and squirrel monkey and the genetic DBA/2 J mouse model) with distinct durations of IOP elevation. While BIRB 796 did not influence IOP, treatment over four weeks in rats prevented degradation of anterograde axonal transport to the superior colliculus and degeneration in the optic nerve. Treatment over months in the chronic DBA/2 J model and in the squirrel monkey model reduced expression and activation of p38 downstream targets in the retina and brain but did not rescue RGC axon transport or degeneration, suggesting the efficacy of BIRB 796 in preventing associated degeneration of the RGC projection depends on the duration of the experimental model. These results emphasize the importance of evaluating potential therapeutic compounds for neuroprotection in multiple models using elongated treatment paradigms for an accurate assessment of efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“topical ocular delivery of the p38 inhibitor BIRB 796 showed a neuroprotective effect in animal models of glaucoma, although the intraocular pressure was not affected [ 129 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
The number of people with glaucoma worldwide in 2010 and 2020
Quigley, H. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.081224 · Cited by 7,394
Heijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,320
(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Factors for Glaucoma Progression and the Effect of Treatment: The Early Manifest Glaucoma Trial
Leske, M. C. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.48 · Cited by 2,030
Activation and signaling of the p38 MAP kinase pathway
ZARUBIN, T., & HAN, J. (2005) · Cell Research · doi:10.1038/sj.cr.7290257 · Cited by 1,707
Mechanisms and functions of p38 MAPK signalling
Cuadrado, A., & Nebreda, A. R. (2010) · Biochemical Journal · doi:10.1042/bj20100323 · Cited by 1,676
p38 MAP-Kinases pathway regulation, function and role in human diseases
Cuenda, A., & Rousseau, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.010 · Cited by 1,400
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Cited by
Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Sterling, J. K., Adetunji, M. O., Guttha, S., Bargoud, A. R., Uyhazi, K. E., Ross, A. G., Dunaief, J. L., & Cui, Q. N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108271 · Cited by 148
Adaptive responses to neurodegenerative stress in glaucoma
Calkins, D. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100953 · Cited by 125
Self-citationMAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“Of potential therapeutic interest, topical ocular delivery of the p38 inhibitor BIRB 796 showed a neuroprotective effect in animal models of glaucoma, although the intraocular pressure was not affected [129].”
BackgroundYe, M.-J., & Meng, N. (2021) · Bioengineered · doi:10.1080/21655979.2021.1954742 · Cited by 43
“A p38 MAPK inhibitor has been also reported to improve outcome after glaucoma filtration surgery in clinic or in animals [34,35], suggesting that the activation of MAPKs cascade contributes to the occurrence and development of glaucoma.”
Background
Metadata
- Authors
- Lambert, W. S., Pasini, S., Collyer, J. W., Formichella, C. R., Ghose, P., Carlson, B. J., & Calkins, D. J.
- Affiliations
- Vanderbilt University Medical Center (US)
- Corresponding author
- Calkins, David J.
- Venue
- Scientific Reports
- Published
- 2020-05-22
- Volume
- 10
- Issue
- 1
- Pages
- 8535-8535
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7244559
- OpenAlex
- W3027976236
- Cited by
- 21
- References
- 89
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 6 · 2022: 2 · 2021: 4 · 2020: 2
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Glaucoma Research Foundation
- Research to Prevent Blindness
- Vanderbilt University (DK59637, DK20593, DK58404, CA68485, EY08126)
- National Institutes of Health (DK-59637, EY08126, CA68485, DK 20593, DK-58404, CA68485, DK20593, DK58404, DK59637 and EY08126)
- Vanderbilt Vision Research Center, Vanderbilt University (P30 EY-08126)
- National Eye Institute (R01EY017427, R01EY024997, P30EY008126)
- National Cancer Institute (P30CA068485)
- National Institute of Diabetes and Digestive and Kidney Diseases (U24DK059637, P30DK058404, P30DK020593)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- glaucoma, p38 MAPK inhibition, BIRB-796, neuroprotection, retinal ganglion cell death, axonal transport, superior colliculus, optic nerve degeneration, intraocular pressure elevation, treatment duration, optic neuropathy
- MeSH terms
- Animals, Axonal Transport, Disease Models, Animal, Glaucoma, Intraocular Pressure, Male, Mice, Inbred DBA, Naphthalenes, Optic Nerve, Phenylurea Compounds, Pyrazoles, Retinal Ganglion Cells, Saimiri, Neuroprotective Agents, Protein Kinase Inhibitors, p38 Mitogen-Activated Protein Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma. https://app.cochat.ai/papers/10.1038/s41598-020-65374-6
- The paper
- Lambert, W. S., Pasini, S., Collyer, J. W., Formichella, C. R., Ghose, P., Carlson, B. J., & Calkins, D. J. (2020). Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma. Scientific Reports. https://doi.org/10.1038/s41598-020-65374-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.